startup
Aptadir Therapeutics
Aptadir Therapeutics develops innovative therapies for difficult-to-treat genetic diseases.
- 机会评分
- 90 / 100
- 累计融资
- $45M
- 融资阶段
- seed
- 成立年份
- unknown
- 地区
- Global
- 阶段
- seed
八个维度
Company · Problem · Solution · Target Customer · Business Model · Funding · Competitors · Why NowCompany
Aptadir Therapeutics is a Milan-based biotech company focused on novel treatments for genetic conditions.
Problem
Current treatments for many genetic diseases are limited or ineffective.
Solution
Aptadir develops innovative therapies targeting difficult-to-treat genetic conditions.
Target Customer
Patients with genetic diseases and pharmaceutical companies seeking new treatments.
Business Model
Revenue generated through drug development partnerships and licensing agreements.
Funding
Raised $45 million in seed funding for drug development and clinical trials.
Competitors
该维度暂无可核实信息(unknown)
Why Now
Increasing demand for effective treatments for genetic diseases and advancements in biotech.
来源与 AI 标注
模型 · prompt 版本 · 生成时间 · 来源链接相关项目与同赛道
按赛道继续看相关项目4 家
| 公司 | 赛道 | 评分 |
|---|---|---|
| Breye TherapeuticsOral therapies for retinal diseases | BiotechHealthcare | 90 |
| Sweden’s OmnioAdvanced therapy for chronic wounds | BiotechHealthcare | 75 |
| Mantis人类数字双胞胎 | B2BAIBiotech | 70 |
| Uncommon Therapeutics专注于开发多款十亿级药物的生物技术公司 | HealthcareTherapeuticsBiotech | 70 |
同赛道入口按赛道继续看
数据来自公开渠道与 AI 解读,仅供参考,不构成投资建议。信息可能滞后或有误,决策请以公司官网与官方披露为准。